Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Tran, 2021, Using cell-free DNA for HCC surveillance and prognosis, JHEP Rep, 3 Ye, 2019, Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA, Mol Cancer, 18, 114, 10.1186/s12943-019-1043-x Yang, 2019, Circulating tumor DNA and hepatocellular carcinoma, Semin Liver Dis, 39, 452, 10.1055/s-0039-1688503 Parackal, 2019, Comparison of Roche Cell-Free DNA collection Tubes® to Streck Cell-Free DNA BCT® s for sample stability using healthy volunteers, Pract Lab Med, 16 Zhao, 2019, Performance comparison of blood collection tubes as liquid biopsy storage system for minimizing cfDNA contamination from genomic DNA, J Clin Lab Anal, 33, 10.1002/jcla.22670 Bernabe, 2017, What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?, Eur J Cancer, 81, 66, 10.1016/j.ejca.2017.04.022 Deans, 2019, IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing, Virchows Arch, 474, 681, 10.1007/s00428-019-02571-3 Shu, 2017, Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types, Sci Rep, 7, 583, 10.1038/s41598-017-00520-1 Huang, 2016, Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity, J Cancer, 7, 1907 Ikeda, 2018, Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma: implications for targeted therapeutics, Mol Cancer Ther, 17, 1114, 10.1158/1535-7163.MCT-17-0604 Howell, 2019, Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma, Eur J Cancer, 116, 56, 10.1016/j.ejca.2019.04.014 Kaseb, 2019, Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA, Clin Cancer Res, 25, 6107, 10.1158/1078-0432.CCR-18-3341 An, 2019, The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma, Am J Transl Res, 11, 6462 Fujii, 2021, Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, J Exp Clin Cancer Res, 40, 215, 10.1186/s13046-021-02016-3 Kim, 2020, MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma, Sci Rep, 10 Totoki, 2014, Trans-ancestry mutational landscape of hepatocellular carcinoma genomes, Nat Genet, 46, 1267, 10.1038/ng.3126 Guichard, 2012, Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma, Nat Genet, 44, 694, 10.1038/ng.2256 Liao, 2016, Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing, Oncotarget, 7, 40481, 10.18632/oncotarget.9629 Cai, 2019, Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma, Clin Cancer Res, 25, 5284, 10.1158/1078-0432.CCR-18-3477 Xiong, 2019, Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma, Cancer Manag Res, 11, 5745, 10.2147/CMAR.S197455 Yang, 2021, Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers, J Immunother Cancer, 9 von Felden, 2021, Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma, Oncogene, 40, 140, 10.1038/s41388-020-01519-1 Lim, 2018, Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma, Clin Cancer Res, 24, 4650, 10.1158/1078-0432.CCR-17-3588 Ikeda, 2018, Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma, Oncologist, 23, 586, 10.1634/theoncologist.2017-0479 Hussain, 2007, TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer, Oncogene, 26, 2166, 10.1038/sj.onc.1210279 Javanmard, 2020, Investigation of CTNNB1 gene mutations and expression in hepatocellular carcinoma and cirrhosis in association with hepatitis B virus infection, Infect Agent Cancer, 15, 37, 10.1186/s13027-020-00297-5 Nault, 2019, The role of telomeres and telomerase in cirrhosis and liver cancer, Nat Rev Gastroenterol Hepatol, 16, 544, 10.1038/s41575-019-0165-3 Oh, 2019, Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with sorafenib, BMC Cancer, 19, 292, 10.1186/s12885-019-5483-x Jin, 2021, Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection, Mol Oncol, 15, 2377, 10.1002/1878-0261.13041 Xu, 2015, Non-invasive analysis of genomic copy number variation in patients with hepatocellular carcinoma by next generation DNA sequencing, J Cancer, 6, 247 Meng, 2021, Noninvasive detection of hepatocellular carcinoma with circulating tumor DNA features and alpha-fetoprotein, J Mol Diagn, 23, 1174, 10.1016/j.jmoldx.2021.06.003 Jiang, 2015, Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients, Proc Natl Acad Sci U S A, 112, E1317, 10.1073/pnas.1500076112 Wang, 2021, Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments, Cancer Sci, 112, 4772, 10.1111/cas.15128 Dor, 2018, Principles of DNA methylation and their implications for biology and medicine, Lancet, 392, 777, 10.1016/S0140-6736(18)31268-6 Weirich, 2008, The septin family of GTPases: architecture and dynamics, Nat Rev Mol Cell Biol, 9, 478, 10.1038/nrm2407 Oussalah, 2018, Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma, EBioMedicine, 30, 138, 10.1016/j.ebiom.2018.03.029 Li, 2020, SEPT9 gene methylation as a noninvasive marker for hepatocellular carcinoma, Dis Markers, 2020, 10.1155/2020/6289063 Wong, 2000, Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients, Clin Cancer Res, 6, 3516 Wu, 2017, Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population, Carcinogenesis, 38, 1021, 10.1093/carcin/bgx078 Zhang, 2007, Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA, Clin Cancer Res, 13, 2378, 10.1158/1078-0432.CCR-06-1900 Wen, 2015, Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients, Cell Res, 25, 1250, 10.1038/cr.2015.126 Hu, 2017, Hypomethylated ubiquitin-conjugating enzyme2 Q1 (UBE2Q1) gene promoter in the serum is a promising biomarker for hepatitis B virus-associated hepatocellular carcinoma, Tohoku J Exp Med, 242, 93, 10.1620/tjem.242.93 Chan, 2016, Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends, Proc Natl Acad Sci U S A, 113, E8159, 10.1073/pnas.1615800113 Jiang, 2018, Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma, Proc Natl Acad Sci U S A, 115, E10925, 10.1073/pnas.1814616115 Jiang, 2020, Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation, Cancer Discov, 10, 664, 10.1158/2159-8290.CD-19-0622 Li, 2020, Cell-free virus-host chimera DNA from hepatitis B virus integration sites as a circulating biomarker of hepatocellular cancer, Hepatology, 72, 2063, 10.1002/hep.31230 Zhang, 2020, Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing, BMC Med, 18, 200, 10.1186/s12916-020-01667-x Zheng, 2021, The landscape of cell-free HBV integrations and mutations in cirrhosis and hepatocellular carcinoma patients, Clin Cancer Res, 27, 3772, 10.1158/1078-0432.CCR-21-0002 Liu, 2021, NGS-based accurate and efficient detection of circulating cell-free mitochondrial DNA in cancer patients, Mol Ther Nucleic Acids, 23, 657, 10.1016/j.omtn.2020.12.017 Labgaa, 2018, A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma, Oncogene, 37, 3740, 10.1038/s41388-018-0206-3 Ng, 2018, Genetic profiling using plasma-derived cell-free DNA in therapy-naive hepatocellular carcinoma patients: a pilot study, Ann Oncol, 29, 1286, 10.1093/annonc/mdy083 Zeng, 2018, Overexpression of EPS8L3 promotes cell proliferation by inhibiting the transactivity of FOXO1 in HCC, Neoplasma, 65, 701, 10.4149/neo_2018_170725N503 Rothwell, 2019, Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study, Nat Med, 25, 738, 10.1038/s41591-019-0380-z Heitzer, 2013, Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing, Genome Med, 5, 30, 10.1186/gm434 Iyer, 2010, Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients, Exp Mol Pathol, 88, 107, 10.1016/j.yexmp.2009.09.012 Yeo, 2005, High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma, Liver Int, 25, 266, 10.1111/j.1478-3231.2005.01084.x Cai, 2019, Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma, Gut, 68, 2195, 10.1136/gutjnl-2019-318882 Qu, 2019, Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy, Proc Natl Acad Sci U S A, 116, 6308, 10.1073/pnas.1819799116 Kisiel, 2019, Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation, Hepatology, 69, 1180, 10.1002/hep.30244 Bai, 2021, DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma, Aging (Albany NY), 13, 17592, 10.18632/aging.203249 Lewin, 2021, Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study, BMC Gastroenterol, 21, 136, 10.1186/s12876-021-01714-8 Wang, 2021, Circulating tumour DNA methylation in hepatocellular carcinoma diagnosis using digital droplet PCR, J Int Med Res, 49 Chalasani, 2021, A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma, Clin Gastroenterol Hepatol, 19, 2597, 10.1016/j.cgh.2020.08.065 Chen, 2021, Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients, Cell Res, 31, 589, 10.1038/s41422-020-00457-7 Shen, 2020, TP53 R249S mutation detected in circulating tumour DNA is associated with prognosis of hepatocellular carcinoma patients with or without hepatectomy, Liver Int, 40, 2834, 10.1111/liv.14581 Wang, 2020, Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma, Ann Transl Med, 8, 237, 10.21037/atm.2019.12.154 Xu, 2017, Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma, Nat Mater, 16, 1155, 10.1038/nmat4997 Zhao, 2014, Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma, Clin Epigenetics, 6, 30, 10.1186/1868-7083-6-30 Zhou, 2021, Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment, J Cancer, 12, 5423 Zhu, 2020, Durable complete response to alectinib in a lung adenocarcinoma patient with brain metastases and low-abundance EML4-ALK variant in liquid biopsy: a case report, Front Oncol, 10, 1259, 10.3389/fonc.2020.01259 Goodsaid, 2019, The labyrinth of product development and regulatory approvals in liquid biopsy diagnostics, Clin Transl Sci, 12, 431, 10.1111/cts.12657 Wang, 2021, Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: a case report, J Int Med Res, 49 Ignatiadis, 2021, Liquid biopsy enters the clinic - implementation issues and future challenges, Nat Rev Clin Oncol, 18, 297, 10.1038/s41571-020-00457-x Heidrich, 2021, Liquid biopsies: potential and challenges, Int J Cancer, 148, 528, 10.1002/ijc.33217 Zhang, 2021, Clinical application value of circulating cell-free DNA in hepatocellular carcinoma, Front Mol Biosci, 8, 10.3389/fmolb.2021.736330 Rolfo, 2018, Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC, J Thorac Oncol, 13, 1248, 10.1016/j.jtho.2018.05.030 Salvianti, 2020, The pre-analytical phase of the liquid biopsy, N Biotechnol, 55, 19 Cheng, 2021, Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions, CA Cancer J Clin, 71, 176, 10.3322/caac.21650 Nesic, 2021, Optimization of preanalytical variables for cfDNA processing and detection of ctDNA in archival plasma samples, Biomed Res Int, 2021, 10.1155/2021/5585148 Connors, 2020, International liquid biopsy standardization alliance white paper, Crit Rev Oncol Hematol, 156, 10.1016/j.critrevonc.2020.103112 Geeurickx, 2020, Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics, Mol Aspects Med, 72, 100828, 10.1016/j.mam.2019.10.005 Lampignano, 2020, Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows, Clin Chem, 66, 149, 10.1373/clinchem.2019.306837 Chai, 2020, External quality assurance of current technology for the testing of cancer-associated circulating free DNA variants, Pathol Oncol Res, 26, 1595, 10.1007/s12253-019-00744-8 Wan, 2017, Liquid biopsies come of age: towards implementation of circulating tumour DNA, Nat Rev Cancer, 17, 223, 10.1038/nrc.2017.7